SEARCH:      Monitor Keywords |  Custom RSS

Organic compounds -- part of the class 532-570 series May archived by USPTO category 05/11

20110124855 - Method for isolation of laurolactam from a laurolactam synthesis process stream: A process for purifying laurolactam by means of integrated connection of distillation and crystallization is provided. The crystallization is performed as a solution or melt crystallization. The process reduces thermal stress applied to the laurolactam stream and improved yields are obtained. Raw materials are recovered and recycled in the production... Agent: Evonik Degussa Gmbh

20110118459 - High performance luminescent compounds: Embodiments relate to the field of chemistry and biochemistry, and, more specifically, to novel near-infrared dyes that are photostable and resistant to quenching. The dyes belong to a novel family of squaraine rotaxanes, and they are particularly well-suited for use in biological applications. Also disclosed are methods of synthesizing the... Agent: Molecular Targeting Technologies, Inc.

20110118460 - Process for the synthesis of quetiapine: The present invention relates to a process for the synthesis of quetiapine. In particular, a process is provided for the synthesis of quetiapine of formula (A) comprising reacting dibenzo[b,f][1,4]thiazepin-11(10H)-one, intermediate (I) with phosphorous oxychloride to give 11-chlorodibenzo[b,f][1,4]thiazepine, intermediate (II) wherein the said reaction of intermediate (I) to intermediate (II) is... Agent:

20110112287 - Carbon nanoparticles, which are covalently bound via a bridge molecule to a target molecule, and a method for the production thereof: A method for covalently binding target molecules to carbon nanoparticles via at least one bridge molecule includes converting carbon nanoparticles to acyl carbon nanoparticles using a carbonyl compound of the at least one bridge molecule in the presence of a Lewis acid under Friedel-Crafts conditionsm, where the acyl carbon nanoparticles... Agent: Karlsruher Institut Fuer Technologie

20110112288 - Metal porphyrin catalyzed olefin aziridination with sulfonyl azides: Cobalt(II) complex of P1 [Co(P1)], a new porphyrin that was designed on the basis of potential hydrogen bonding interactions in the metal-nitrene intermediate, is a highly active catalyst for olefin aziridination with azides. The [Co(P1)]-based system can be effectively employed for different combinations of aromatic olefins and arysulfonyl azides, synthesizing... Agent: University Of South Florida

20110112289 - Compounds useful as ligands and particularly as organic chromophores for complexing lanthanides and applications thereof: b

20110112290 - process for the preparation of quetiapine: The invention relates to a method for the preparation of 11-(4-[2-(2-hydroxyethoxy)ethyl]-1-piperazinyl]dibenzo[b,f]-1,4-thiazepine and pharmaceutically acceptable salts thereof comprising the reaction of 1-[2-(hydroxyethoxy)-ethyl]piperazine with dibenzo[b,f][1,4]thiazepin-11-ylamine.... Agent: Fermion Oy

20110112291 - Stabilization of conjugates comprising a thiourea linker: The present invention discloses a composition containing a conjugate comprising two moieties covalently linked by a thiourea linker and thiourea or a derivative thereof in free form. It also relates to a method for stabilizing a conjugate comprising two moieties covalently linked by a thiourea linker is described the method... Agent:

20110105745 - Compositions and methods of making a photoactive agent: An improved two stage reaction process for production of mono-L-aspartyl chlorin e6. In a first stage, the activation reaction between chlorin e6 and a carbodiimide produces a previously unknown anhydride in an activation reaction product. This reaction product is purified to remove a significant proportion of the precursors of di-L-aspartyl... Agent: Light Sciences Oncology, Inc.

20110105746 - Method of making porphyrins:

20110105747 - Quinoline derivative and quinazoline derivative inhibiting self-phosphorylation of hepatocytus proliferator receptor, and medicinal composition containing the same: wherein X=CH or N; Z=O or S; L=O or S; M=CR10R11, wherein R10 and R11=H, alkyl, or alkoxy, NR12 wherein R12=H or alkyl; R1, R2, and R3=H or optionally substituted alkoxy; R4=H; R5-8=H, halogen, alkoxy or the like; and R9=alkyl optionally substituted by -T-R15, or —NR16R17 wherein T=O, S, or... Agent: Kirin Beer Kabushiki Kaisha